Raymond James Financial Weighs in on TSE:GUD FY2025 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Investment analysts at Raymond James Financial upped their FY2025 EPS estimates for Knight Therapeutics in a research note issued to investors on Wednesday, June 18th. Raymond James Financial analyst M. Freeman now expects that the company will post earnings per share of $0.15 for the year, up from their previous estimate of $0.14. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James Financial also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at $0.07 EPS.

Other equities research analysts have also issued reports about the stock. Stifel Nicolaus raised their price objective on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a report on Tuesday, March 25th. Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group set a C$6.50 price objective on shares of Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 9th. Two research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Knight Therapeutics currently has a consensus rating of “Strong Buy” and a consensus price target of C$7.15.

Knight Therapeutics Stock Down 1.7%

Shares of Knight Therapeutics stock opened at C$5.84 on Thursday. Knight Therapeutics has a 52-week low of C$5.09 and a 52-week high of C$6.45. The company has a 50 day moving average of C$5.87 and a 200 day moving average of C$5.69. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The company has a market capitalization of C$590.72 million, a P/E ratio of -19.50, a P/E/G ratio of -1,013.50 and a beta of 0.50.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.